Literature DB >> 33814982

Hyperglycemia and Correlated High Levels of Inflammation Have a Positive Relationship with the Severity of Coronavirus Disease 2019.

Wen Zhang1,2, Chuanwei Li2,3,4, Yu Xu1,3,5, Binfeng He1, Mingdong Hu1,2,3, Guoqiang Cao2,3,6, Li Li2,3,6, Shuang Wu3, Xia Wang1, Chun Zhang1, Jianping Zhao7, Jungang Xie7, Zihui Xu8, Qi Li1,2,3, Guansong Wang1.   

Abstract

OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a considerable global public health threat. This study sought to investigate whether blood glucose (BG) levels or comorbid diabetes are associated with inflammatory status and disease severity in patients with COVID-19.
METHODS: In this retrospective cohort study, the clinical and biochemical characteristics of COVID-19 patients with or without diabetes were compared. The relationship among severity of COVID-19, inflammatory status, and diabetes or hyperglycemia was analyzed. The severity of COVID-19 in all patients was determined according to the diagnostic and treatment guidelines issued by the Chinese National Health Committee (7th edition).
RESULTS: Four hundred and sixty-one patients were enrolled in our study, and 71.58% of patients with diabetes and 13.03% of patients without diabetes had hyperglycemia. Compared with patients without diabetes (n = 366), patients with diabetes (n = 95) had a higher leucocyte count, neutrophil count, neutrophil to lymphocyte ratio (NLR), and erythrocyte sedimentation rate (ESR). There was no association between severity of COVID-19 and known diabetes adjusted for age, sex, body mass index (BMI), known hypertension, and coronary heart disease. The leucocyte count, NLR, and C-reactive protein (CRP) level increased with increasing BG level. Hyperglycemia was an independent predictor of critical (OR 4.00, 95% CI 1.72-9.30) or severe (OR 3.55, 95% CI 1.47-8.58) COVID-19, and of increased inflammatory levels (high leucocyte count (OR 4.26, 95% CI 1.65-10.97), NLR (OR 2.76, 95% CI 1.24-6.10), and CRP level (OR 2.49, 95% CI 1.19-5.23)), after adjustment for age, sex, BMI, severity of illness, and known diabetes.
CONCLUSION: Hyperglycemia was positively correlated with higher inflammation levels and more severe illness, and it is a risk factor for the increased severity of COVID-19. The initial measurement of plasma glucose levels after hospitalization may help identify a subset of patients who are predisposed to a worse clinical course.
Copyright © 2021 Wen Zhang et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33814982      PMCID: PMC7977979          DOI: 10.1155/2021/8812304

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  24 in total

1.  The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia.

Authors:  Finlay A McAlister; Sumit R Majumdar; Sandra Blitz; Brian H Rowe; Jacques Romney; Thomas J Marrie
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study.

Authors:  Angus Forbes; Trevor Murrells; Henrietta Mulnier; Alan J Sinclair
Journal:  Lancet Diabetes Endocrinol       Date:  2018-04-16       Impact factor: 32.069

Review 4.  15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020.

Authors: 
Journal:  Diabetes Care       Date:  2020-01       Impact factor: 19.112

5.  Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?

Authors:  Celestino Sardu; Nunzia D'Onofrio; Maria Luisa Balestrieri; Michelangela Barbieri; Maria Rosaria Rizzo; Vincenzo Messina; Paolo Maggi; Nicola Coppola; Giuseppe Paolisso; Raffaele Marfella
Journal:  Diabetes Care       Date:  2020-05-19       Impact factor: 19.112

6.  Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study.

Authors:  F Y Alqahtani; F S Aleanizy; R Ali El Hadi Mohamed; M S Alanazi; N Mohamed; M M Alrasheed; N Abanmy; T Alhawassi
Journal:  Epidemiol Infect       Date:  2018-11-05       Impact factor: 2.451

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 9.  Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.

Authors:  Bo Li; Jing Yang; Faming Zhao; Lili Zhi; Xiqian Wang; Lin Liu; Zhaohui Bi; Yunhe Zhao
Journal:  Clin Res Cardiol       Date:  2020-03-11       Impact factor: 6.138

10.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

View more
  6 in total

Review 1.  Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Abraham Degarege; Zaeema Naveed; Josiane Kabayundo; David Brett-Major
Journal:  Pathogens       Date:  2022-05-10

Review 2.  Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin.

Authors:  Clifford J Bailey; Mike Gwilt
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

3.  Association of admission blood glucose level and clinical outcomes in elderly community-acquired pneumonia patients with or without diabetes.

Authors:  Weijian Zeng; Xiaoxing Huang; Weijie Luo; Mingqian Chen
Journal:  Clin Respir J       Date:  2022-07-24       Impact factor: 1.761

4.  Hyperglycemia and Hypoglycemia Are Associated with In-Hospital Mortality among Patients with Coronavirus Disease 2019 Supported with Extracorporeal Membrane Oxygenation.

Authors:  Kuk Hui Son; Woong-Han Kim; Jae Gun Kwak; Chang-Hyu Choi; Seok In Lee; Ui Won Ko; Hyoung Soo Kim; Haeyoung Lee; Euy Suk Chung; Jae-Bum Kim; Woo Sung Jang; Jae Seung Jung; Jieon Kim; Young Kyung Yoon; Seunghwan Song; Minji Sung; Myung Hun Jang; Young Sam Kim; In-Seok Jeong; Do Wan Kim; Tae Yun Kim; Soon Jin Kim; Su Wan Kim; Joonhwa Hong; Hyungmi An
Journal:  J Clin Med       Date:  2022-08-30       Impact factor: 4.964

5.  Effect of Glycated Hemoglobin (HbA1c) and Duration of Disease on Lung Functions in Type 2 Diabetic Patients.

Authors:  Hawra Bin Maan; Sultan Ayoub Meo; Fawziah Al Rouq; Imran Muhammad Umar Meo; Milagros E Gacuan; Joud Mohammed Alkhalifah
Journal:  Int J Environ Res Public Health       Date:  2021-06-29       Impact factor: 3.390

Review 6.  Consequences of COVID-19 for the Pancreas.

Authors:  Urszula Abramczyk; Maciej Nowaczyński; Adam Słomczyński; Piotr Wojnicz; Piotr Zatyka; Aleksandra Kuzan
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.